53% in the 40-mg cabozantinib ccRCC cohort58% in the 60-mg cabozantinibccRCC cohortORR was 31% in nccRCC cohort47% P11% ChOther 25%ORR independent of the PD-L1 status. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.